8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

          Date of Report (Date of earliest event reported): May 6, 2004



                       SANGUI BIOTECH INTERNATIONAL, INC.
             -----------------------------------------------------
             (Exact name of Registrant as specified in its charter)

                                    Colorado
                                    --------
          (State or other jurisdiction of Incorporation or organization


       000-21271                                        84-1330732
 -----------------------                                ----------
(Commission File Number)                    (I.R.S. Employer Identification No.)

                Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
                ------------------------------------------------
               (Address of principal executive offices)(Zip Code)

                               011-49-2302-915-204
                               -------------------
              (Registrant's telephone number, including area code)


                                       N/A
          (Former name or former address, if changed since last report)







Item 9.           Regulation FD Disclosure

         On May 6, 2004 Sangui Biotech International, Inc. (the "Company")
issued a press release announcing that its German subsidiary, Sangui Biotech
GmbH and Mercatura Cosmetics Biotech AG, Achim, Germany, have signed a letter of
intent aiming at marketing "Pure Moisture", an anti-aging nano-formulation
developed by Sangui. Under the proposed agreement Sangui will license to
Mercatura the exclusive right to sell the nano-emulsion in German and
international markets. Mercatura plans to include this product under its
"Wunderkind" brand, jointly marketed by Mercatura and German top designer
Wolfgang Joop. A copy of the press release is furnished as Exhibit 99.2 to this
report.


         The information in this Current Report on Form 8-K, including the
exhibit, is furnished under "Item 2. Management's Discussion and Analysis of
Financial Condition" in accordance with SEC Release No. 33-8216. Furthermore,
the information in this Current Report on Form 8-K, including the exhibit, shall
not be deemed to be incorporated by reference into the filings of the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, as amended.







                                   SIGNATURES

         Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the Undersigned, thereunto duly authorized.

                                            Sangui Biotech International, Inc.
                                            (Registrant)


Date: May 7, 2004                           /s/ Wolfgang Barnikol
                                            ----------------------------
                                            By: Wolfgang Barnikol
                                            Its:  President, CEO and CFO






                                INDEX TO EXHIBITS


Exhibit Number                  Exhibit
- --------------                  -------
         99.1              Press Release dated May 6, 2004*

* This exhibit is furnished to, but not filed with, the Commission by inclusion
herein.

EX-99

                                  Exhibit 99.1

                                [OBJECT OMITTED]
                                 (Sangui Biotech
                         International, Inc. Letterhead)



SANGUI AND MERCATURA SIGN LETTER OF INTENT TO MARKET ANTI-AGING FORMULATION

Witten, May 6, 2004 - SanguiBioTech GmbH, Witten, Germany, a wholly owned
subsidiary of SanguiBioTech International, Inc. (NASD OTCBB: SGBI), and
Mercatura Cosmetics Biotech AG, Achim, Germany, have signed a letter of intent
aiming at marketing "Pure Moisture", an anti-aging nano-formulation developed by
Sangui. Under the proposed agreement Sangui will license to Mercatura the
exclusive right to sell the nano-emulsion in German and international markets.
Mercatura plans to include this product under its "Wunderkind" brand, jointly
marketed by Mercatura and German top designer Wolfgang Joop. "Pure moisture"
recently received top marks in skin tolerance and moisturization by Dermatest,
renowned independent German dermatological research and testing institute.




For more information:
Joachim Fleing
Phone: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de




This news release includes  statements,  other than historical fact, that may be
deemed  forward-looking.  These  statements  may be accompanied by words such as
"believe,"  "estimate,"  "project,"  "expect,"  "anticipate,"  or "predict" that
conveys the uncertainty of future events or outcomes. These statements are based
on assumptions that the Company believes are reasonable;  however,  many factors
could cause the Company's actual results in the future to differ materially from
the  forward-looking  statements  made herein and in any other documents or oral
presentations  made by, or on behalf of, the Company.  Important  factors  which
could cause actual results to differ  materially  from those in  forward-looking
statements  include,  among others, the ability to obtain additional  financing,
which is not assured; rapid technological  developments and changes; problems in
developments  of the  Company's  products;  price  and  product  competition  by
competitors; general economic conditions; and factors discussed in the Company's
SEC filings.  Shareholders are cautioned that the forward-looking statements are
not guarantees of future performance and that developments  different from those
projected in the  forward-looking  statements  can be expected.  Sangui does not
intend (and is not legally  obligated)  to update  publicly any  forward-looking
statements.